Tengion (Tengion) Ending Cash Position : $5.73 Mil (As of Sep. 2014)

View and export this data going back to 2010. Start your Free Trial

What is Tengion Ending Cash Position?

Tengion's Ending Cash Position for the quarter that ended in Sep. 2014 was $5.73 Mil.

Tengion's quarterly Ending Cash Position declined from Mar. 2014 ($15.37 Mil) to Jun. 2014 ($10.12 Mil) and declined from Jun. 2014 ($10.12 Mil) to Sep. 2014 ($5.73 Mil).

Tengion's annual Ending Cash Position declined from Dec. 2011 ($9.24 Mil) to Dec. 2012 ($7.54 Mil) but then increased from Dec. 2012 ($7.54 Mil) to Dec. 2013 ($21.51 Mil).

Tengion Ending Cash Position Historical Data

The historical data trend for Tengion's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tengion Ending Cash Position Chart

Tengion Annual Data

Trend

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Ending Cash Position

Get a 7-Day Free Trial

16.80

11.97

9.24

7.54

21.51

Tengion Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Ending Cash Position	Get a 7-Day Free Trial															27.48	21.51	15.37	10.12	5.73

Tengion Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Tengion's Ending Cash Position for the fiscal year that ended in Dec. 2013 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	7.536	+	13.974
	=	21.51

Tengion's Ending Cash Position for the quarter that ended in Sep. 2014 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	10.124	+	-4.396
	=	5.73

Tengion Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Tengion's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Tengion (Tengion) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tengion Inc (GREY:TNGNQ) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

N/A

Address

3929 Westpoint Boulevard, Suite G, Winston-Salem, NC, USA, 27103

Website

http://www.tengion.com

Tengion Inc is a regenerative medicine company. The company is engaged in discovering, manufacturing and commercializing neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace damaged tissue or organ. Its product candidates seek to eliminate the need to utilize other tissues of the body for a purpose to which they are poorly suited, procure donor organs or administer anti-rejection medications. The company's solution Neo-Kidney Augment is based on its proprietary technology, which uses tubular epithelial cells, procured by a cortical biopsy of the patient's kidney, to create an injectable product candidate that can catalyze the regeneration of functional kidney tissue.

Executives

John L Miclot	director, officer: President and CEO	5005 OLD ORCHARD LANE, GIBSONIA PA 15044
Lorin Randall	director	C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
A Brian Davis	officer: Chf. Fin. Offr, VP Fin.	C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380
Medtronic Inc	10 percent owner	710 MEDTRONIC PKWY, MINNEAPOLIS MN 55432
Johan Christenson	10 percent owner	C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Staffan Lindstrand	10 percent owner	C/O ODLANDER, FREDRIKSON & CO. AB, STRANDVAGEN 5B, STOCKHOLM V7 SE-114 51
Richard Kuntz	director	MEDTRONIC, INC., 710 MEDTRONIC PWKY MS LC 310, MINNEAPOLIS MN 55432
Diane Jorkasky	director	60 MANOR AVENUE, WELLESLEY MA 02482
Mark Stejbach	officer: VP and Chief Commercial Offcr	C/O TENGION, INC., 2900 POTSHOP LANE, SUITE 100, EAST NORRITON PA 19403
Steven Nichtberger	director, officer: President and CEO	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Johnson & Johnson	10 percent owner	ONE JOHNSON & JOHNSON PLZ, NEW BRUNSWICK NJ 08933
Johnson & Johnson Innovation - Jjdc, Inc.	10 percent owner	410 GEORGE STREET, NEW BRUNSWICK NJ 08901
Oak Investment Partners Xi L P	10 percent owner	901 MAIN AVENUE, SUITE 600, NORWALK CT 06851

Tengion (Tengion) Headlines

From GuruFocus

Tengion Inc. Reports Operating Results (10-Q)

By gurufocus 10qk • 05-20-2010